Study Conduct

Icon releases Flex Advantage for patient randomization

Tuesday, January 19, 2016

Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has launched Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomization and clinical supply management capabilities and supports the execution of adaptive trials.

[Read More]

A look at the evolving role of study brokers

Friday, January 15, 2016

For many small to medium-sized investigative sites, the scramble to find clinical study opportunities continues to intensify.  Some sites have become part of informal networks that help find available studies for individual members, while others turn to middlemen or trial management firms, often called study brokers, who are available to assist investigative sites in boosting their business development and lead-generation efforts.

[Read More]

Certara launches a consulting company in China

Tuesday, January 12, 2016

Certara, a global biosimulation technology-enabled drug development company, has launched Certara Strategic Consulting China in Shanghai. This new company is being led by President and CEO Christine Yuying Gao, M.D., Ph.D., former vice president of consulting services at Quantitative Solutions, a global pharmacometrics consulting company. Quantitative Solutions merged with Certara’s Pharsight Consulting Services in July 2015 to form Certara Strategic Consulting.

[Read More]